- The Washington Times - Sunday, February 13, 2005

Vioxx and other pain-relieving drugs have given many people with chronic pain the chance to resume normal lives, but an increase in heart attacks among users of the popular arthritis drug led the manufacturer to pull it from the market and has cast a shadow over similar medications.

Advisers to the Food and Drug Administration will meet this week to see if a balance can be found between benefits from these kinds of prescription drugs and the dangers they might pose.

Over three days beginning Wednesday, two advisory groups will hear from regulators, pharmaceutical companies, researchers, doctors and the public in an effort to understand what went wrong — leading Vioxx to be withdrawn and raising doubts about other drugs — and what needs to be done now.

Merck & Co.’s Vioxx and two similar drugs — Pfizer Inc.’s Celebrex and Bextra, both of which remain on the market — are among a new class called Cox-2 inhibitors used widely to treat arthritis and other chronic conditions.

Clinical trials found few serious problems with the new drugs, but there was an increase in heart attacks and strokes among patients taking part in a long-term trial to gauge the effectiveness of Vioxx in preventing cancer.

As a result, Merck halted the study and pulled Vioxx from the market on Sept. 30.

In a memo to the two FDA advisory committees, the agency’s Center for Drug Evaluation and Research noted that many consumers and scientists have questioned whether any Cox-2 drug should be allowed to remain on sale.

It is not clear how the drugs may cause heart problems. That is one more question the committees will consider.

One suggestion is that because Vioxx seems to increase blood pressure, heart trouble could result.

The withdrawal of Vioxx also raised questions about the safety of Celebrex and Bextra.

A 1999 study of Alzheimer’s patients taking Celebrex indicated that the patients had four times the risk of heart problems. Pfizer contends that definitive conclusions cannot be drawn from that study.

In December, a different study linked Celebrex to increased cardiovascular problems. Pfizer’s president of worldwide development, Dr. Joseph Feczko, said the results in that study were not consistent with a “large body of data” the company had collected.

In November, a preliminary study discussed at the American Heart Association’s annual meeting indicated Bextra more than doubled the risk of heart attack and stroke among heart disease patients.

Pfizer said those findings were “unsubstantiated conclusions” that had not been subjected to independent scientific review, but the company advised regulators that it will add to the Bextra packaging a warning of a potentially fatal skin reaction linked to the drug.

The FDA has received a request from the consumer group Public Citizen to order Celebrex and Bextra from the market, which the agency is reviewing.

While awaiting the findings of the advisory committees, the FDA has urged physicians and patients to use caution with any painkiller.


Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide